Did you develop cancer after prolonged exposure to glyphosate or Roundup® weed killer? If so, we recommend reaching out to our experienced product liability attorneys to get more information on whether you may be entitled to compensation from the product’s manufacturer.
Monsanto, an agricultural biotechnology company now owned by Bayer AG, developed the herbicide Roundup® in the 1970s and placed it on the market in 1974. The active chemical in Roundup® is called glyphosate.
In 2015, the International Agency for Research on Cancer (IARC) issued a report relating to glyphosate. The IARC classified glyphosate as a Group 2A agent, which means that it is probably carcinogenic to humans. The IARC concluded that the cancers most associated with glyphosate exposure are non-Hodgkin lymphoma and its various subtypes. Despite this assessment and report, Monsanto maintains to this day that Roundup® and glyphosate-based products do not pose a health hazard to humans. Monsanto’s statements are misleading and because they have aggressively promoted Roundup® as a safe product for decades, in spite of conflicting evidence, consumers who regularly come in contact with Roundup® may not be adhering to proper safety precautions when using the herbicide.
Farmers, landscapers, municipalities, and residential users, among others, have all relied on Roundup® to control weed overgrowth over the years. Monsanto’s patent to manufacture glyphosate expired in 2000 and since then, other companies have been able to manufacture and sell their own glyphosate-based products, further driving the increase in use and exposure.
Generally, a potential client needs to have been diagnosed with a related cancer after two consecutive years of exposure, with a minimum of eight hours of exposure each year (or a minimum of 16 hours over two years).
- Non-Hodgkin’s Lymphoma (NHL) and its certain
- B- cell lymphomas
(about 85% of all NHLs in the U.S.)
- Diffuse large B-cell lymphoma (DLBCL) (about 33% of all NHLs in the U.S.)
- Follicular lymphoma (about 20% of all lymphomas in the U.S.)
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Burkitt Lymphoma
Lymphoma (Waldenström Macroglobulinemia)
- Hairy cell leukemia (HCL)
- Mantle cell lymphoma (about 5% of lymphomas)
- Marginal zone B-cell lymphomas (about 5–10% of all lymphomas)
- B-Lymphoblastic Lymphoma (LL)
- T-cell lymphomas
(about 15% of NHLs in the U.S.)
- Peripheral T cell lymphomas (PTCL)
- Large Granular Lymphocytic Leukemia (LGL)
- Anaplastic Large Cell Lymphoma (ALCL)
- B- cell lymphomas (about 85% of all NHLs in the U.S.)
What should I do?
If you were diagnosed with Non-Hodgkin Lymphoma or one of its subtypes listed above and have used Roundup®, you may have a legal claim for compensation. Contact our attorneys to discuss your specific legal issues.